| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041969192 |
| P356 | DOI | 10.2165/11200910-000000000-00000 |
| P698 | PubMed publication ID | 21080744 |
| P50 | author | Kate McKeage | Q102146108 |
| P2093 | author name string | Claudine M Chwieduk | |
| P2860 | cites work | Morphine and alternative opioids in cancer pain: the EAPC recommendations | Q24648711 |
| Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors | Q34244033 | ||
| Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control | Q34481299 | ||
| Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain | Q35826726 | ||
| World Health Organization guidelines for cancer pain: a reappraisal | Q36143664 | ||
| Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer | Q36688911 | ||
| Management of breakthrough pain in patients with cancer. | Q37154731 | ||
| The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 | ||
| Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain | Q37263198 | ||
| Formulations of fentanyl for the management of pain | Q39293912 | ||
| Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study | Q39294172 | ||
| Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain | Q39297474 | ||
| Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control | Q39459785 | ||
| Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study | Q44020445 | ||
| Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites | Q44084085 | ||
| Which potent opioid? Important criteria for selection | Q44345650 | ||
| In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance | Q44638919 | ||
| Morphine's immunoregulatory actions are not shared by fentanyl. | Q47754945 | ||
| Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats | Q48462929 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| Histamine Release during Morphine and Fentanyl Anesthesia | Q51863184 | ||
| Management of cancer pain | Q77769507 | ||
| P433 | issue | 17 | |
| P921 | main subject | fentanyl | Q407541 |
| opioid | Q427523 | ||
| P304 | page(s) | 2281-2288 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer | |
| P478 | volume | 70 |
| Q39152290 | Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study |
| Q41936879 | Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care |
| Q92609980 | Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets |
| Q55389816 | Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. |
| Q39214375 | Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain |
| Q38786011 | Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain |
| Q39197889 | Fentanyl Formulations in the Management of Pain: An Update |
| Q39144886 | Multidimensional Treatment of Cancer Pain |
| Q38055713 | Pharmacokinetics of non-intravenous formulations of fentanyl |
| Q37974707 | Pharmacotherapy for breakthrough cancer pain |
| Q57286683 | The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study |
Search more.